Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

PURPOSE: Survival of patients with completely resected non–small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established. This phase III study assessed the impact of postoperative adjuvant gefitinib on overall survival (OS). PATIENTS AND METH...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Goss, Glenwood D., O'Callaghan, Chris, Lorimer, Ian, Tsao, Ming-Sound, Masters, Gregory A., Jett, James, Edelman, Martin J., Lilenbaum, Rogerio, Choy, Hak, Khuri, Fadlo, Pisters, Katherine, Gandara, David, Kernstine, Kemp, Butts, Charles, Noble, Jonathan, Hensing, Thomas A., Rowland, Kendrith, Schiller, Joan, Ding, Keyue, Shepherd, Frances A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2013
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3770864/
https://ncbi.nlm.nih.gov/pubmed/23980091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.1816
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars